CLINICAL_TRIALS
trial_result
· 2025-11-06
Clinical Trial Update: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria [Phase 2]
Summary
A Phase 2 study of CDX-0159 in chronic inducible urticaria has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celldex Therapeutics | Conditions: Chronic Inducible Urticaria | Phase 2 | Status: COMPLETED